Ono Pharmaceutical Co., Ltd.

Vanderbilt University

Kentaro Yashiro

Tetsuji Saito

Daisuke Wakamatsu

Craig William Lindsley

Takahiro Mori

Haruto Kurata

Joshua M Wieting

Kevin M McGowan

Jerod S Denton

Yoko Sekioka

Yuzo Iwaki

Masashi Kato

Adam James Davenport

Christopher Charles Stimson

Takuya Okada

Activator of TREK (TWIK RElated Kchannels) channels

The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases. 

KCNQ2-5 channel activator

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like). 

The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Osaka, Japan

Kentaro Yashiro